Sign in
CompletedPhase 1/2

A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Key facts

Who runs it
Keymed Biosciences Co.Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
88 people enrolled
Started
11 Jul 2022
Ended
29 Mar 2024
Type of study
Interventional, 4 groups
Treatments tested
  • CM326
  • Placebo
Record updated
8 November 2024

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Subjects who are capable of understanding the nature of the study and voluntarily signing the ICF
  • Male or female subjects, aged between 18 and 70 years old (inclusive), with a body mass index (BMI) ≥ 19 kg/m2
  • Diagnosed with Chronic Rhinosinusitis With Nasal Polyps
  • The total NPS score should be at least 3 points, with at least 1 point in each side of the nasal cavity
  • Prior treatment with systemic corticosteroids (SCS) within two years before screening, and/or contraindicate to or intolerance to systemic corticosteroids, and/or with prior surgery to nasal polyps 6 months before the screening
  • Ongoing symptoms for at least 4 weeks before screening:1) Nasal congestion/obstruction; 2) Other symptom, e.g., loss of smell or rhinorrhea

Who cannot take part

  • Have used of systemic immunosuppressants for inflammatory or autoimmune diseases within 8 weeks or 5 half-lives prior to randomization
  • Have initiated leukotriene receptor antagonist therapy within 4 weeks prior to randomization
  • have received allergen-specific immunotherapy that initiated within 3 months prior to randomization or planned to be initiated during the study period
  • Have undergone nasal surgery (including nasal polypectomy) within 6 months prior to screening
  • Have received medium- and short-acting systemic corticosteroids (including oral, intravenous, intramuscular corticosteroids), nasal dripping corticosteroids, traditional Chinese medicine (including systemic and local herbal products preparations) for chronic rhinosinusitis (CRS) within 4 weeks prior to screening, or long-acting systemic corticosteroids
  • With concomitant asthma (including suspected diagnosis of asthma) will be excluded if they meet the following conditions: predicted FEV1 of≤ 60%, or acute exacerbation of asthma within 3 months prior to screening requiring SCS or hospitalization (> 24 hours), or using inhaled corticosteroids (ICS) of > 1000 μg fluticasone propionate or others at equivalent doses
  • Have received live attenuated vaccines within 12 weeks prior to randomization, or during the planned study; or have received inactivated vaccines (e.g., novel coronavirus vaccines) within 30 days prior to randomization
  • With a history of large alcohol consumption or a history of drug abuse within 3 months prior to screening
  • Allergic or intolerant to mometasone furoate spray or CM326/placebo
  • With allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis), Young's syndrome, Kartagener's syndrome or other dyskinetic ciliary syndromes, cystic fibrosis
  • With acute sinusitis, nasal infection, or upper respiratory tract infection at screening
  • Have symptoms or whose CT scan suggests allergic fungal sinusitis
  • With malignant or benign neoplasm of nasal cavities
  • With other uncontrolled serious diseases or recurrent chronic diseases
  • Have severe hepatic and renal impairment
  • With known or suspected immunosuppression, including, but not limited to, the history of invasive opportunistic infections
  • With other medical or non-medical conditions that are not suitable for participation in the study in the opinion of the investigator
  • With antrochoanal polyps
  • With severe deviation of the nasal septum occludes at least one nostril
  • With persistent rhinitis medicamentosas
  • Subjects who are pregnant or planning to become pregnant, or breastfeeding during the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multi-center, randomized, double blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of CM326 in patients with chronic rhinosinusitis with nasal polyps.

The 4 groups in the trial

  • Group 1: 55mg Q2WTreatment being tested

    CM326 55 mg or matched placebo, every 2 weeks, subcutaneous (SC)

    Treatment: CM326 and Placebo

  • Group 2: 110mg Q2WTreatment being tested

    CM326 110 mg or matched placebo, every 2 weeks, subcutaneous (SC)

    Treatment: CM326 and Placebo

  • Group 3: 220mg Q2WTreatment being tested

    CM326 220 mg or matched placebo, every 2 weeks, subcutaneous (SC)

    Treatment: CM326 and Placebo

  • Group 4: 220mg Q4WTreatment being tested

    CM326 220mg or matched placebo, every 4 weeks, subcutaneous (SC)

    Treatment: CM326 and Placebo

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double Blind, Placebo-controlled, Dose Escalation Phase 1b/2a Study to Evaluate the Safety, Tolerability, PK, PD, Immunogenicity and Preliminary Efficacy of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps
Publications
Record updated
8 November 2024